Zinc oxide nanoparticles' potential as a treatment for MDR Klebsiella pneumoniae, which was identified from clinical infections in Iraq

Background: Klebsiella pneumoniae is an agent that can induce a variety of clinically significant infections, like UTI, pyogenic liver abscesses, sepsis, meningitis, pneumonia, and bacteremia. Zinc oxide nanoparticles' in vitro effectiveness against multidrug-resistant (MDR) Klebsiella pneumoniae isolated from different clinical illnesses is the goal of this investigation. Methods: 120 K. pneumoniae Isolates were obtained from individuals suffering from burns, tonsillitis, otitis media, and urinary tract infections. The samples were taken from the Burn Center in Najaf Al-Ashraf, Al-Hakim General Hospital, and Al-Sadder Medical City. They were then transferred to the University of Kufa's Faculty of Science's Advanced Microbiology Laboratory for examination. Multidrug resistance: Out of all the isolates, 60 were found to be multidrug-resistant based on biofilm formation evaluation and antibacterial susceptibility testing. Results: The findings showed that zinc oxide nanoparticles significantly decrease MDR in K. pneumoniae. Zinc oxide nanoparticles' bacterial inhibition zones and effect on biofilm formation also increased gradually with increasing concentrations (One, two, three, and four hundred μg/ml). Conclusion: Results demonstrate that as the concentration of zinc oxide nanoparticles increases, the inhibition zone for MDR K. pneumoniae progressively increases and biofilm formation decreases, further proving that the tested nanoparticles are capable of acting as a potential antimicrobial agent.